Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 16;16(5):754.
doi: 10.3390/ph16050754.

RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France

Marie Terroir  1 , Chloé Lamesa  2 , Mehdi Krim  1 , Lavinia Vija  1 , Jean-Sébastien Texier  1 , Thibaut Cassou-Mounat  1 , Jean-Pierre Delord  3 , Delphine Vallot  4 , Frédéric Courbon  1
Affiliations
Review

RadioLigand Therapy with [177Lu]Lu-PSMA-617 for Salivary Gland Cancers: Literature Review and First Compassionate Use in France

Marie Terroir et al. Pharmaceuticals (Basel). .

Abstract

Salivary gland cancers are rare tumors comprising a large group of heterogeneous tumors with variable prognosis. Their therapeutic management at a metastatic stage is challenging due to the lack of therapeutic lines and the toxicity of treatments. [177Lu]Lu-PSMA-617 (prostate-specific membrane antigen) is a vectored radioligand therapy (RLT) initially developed to treat castration-resistant metastatic prostate cancer with encouraging results in terms of efficacy and toxicity. Many malignant cells could be treated with [177Lu]Lu-PSMA-617 as long as they express PSMA as a consequence of androgenic pathway activation. RLT may be used when anti-androgen hormonal treatment has failed, particularly in prostate cancer. [177Lu]Lu-PSMA-617 has been proposed in certain salivary gland cancers, though the expression of PSMA is demonstrated by a significant uptake using [68Ga]Ga-PSMA-11 PET scan. This theranostic approach could be a new therapeutic option, warranting prospective investigation in a larger cohort. We review the literature on this subject and offer a clinical illustration of compassionate use in France as a perspective for administering [177Lu]Lu-PSMA-617 in salivary gland cancer.

Keywords: [177Lu]Lu-PSMA-617; salivary gland cancer; vectored radioligand therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
[68Ga]Ga-PSMA-11 PET-CT before (A) and after (B) 4 cycles of RLT by [177Lu]Lu-PSMA-617 with left humeral head lesion (black and white arrow).
See this image and copyright information in PMC

References

    1. Skálová A., Hyrcza M.D., Leivo I. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Salivary Glands. Head Neck Pathol. 2022;16:40–53. doi: 10.1007/s12105-022-01420-1. - DOI - PMC - PubMed
    1. Nishida H., Kondo Y., Kusaba T., Kadowaki H., Daa T. Immunohistochemical Reactivity of Prostate-Specific Membrane Antigen in Salivary Gland Tumors. Head Neck Pathol. 2022;16:427–433. doi: 10.1007/s12105-021-01376-8. - DOI - PMC - PubMed
    1. Van Boxtel W., Uijen M.J.M., Verhaegh G.W., Willems S.M., Jonker M.A., PALGA Group. Schalken J.A., van Engen-van Grunsven I.C.H., van Herpen C.M.L. Prognostic value of PSMA, c-MET and E-cadherin in salivary duct carcinoma. Oral Oncol. 2020;110:105018. doi: 10.1016/j.oraloncology.2020.105018. - DOI - PubMed
    1. Aegerter D.P., Cosmidis D.A. Participants Bureau REFCOR. [(accessed on 19 September 2022)]. Available online: http://refcor.org/files/116/recommandations/refcor_glandes_salivaires.pdf.
    1. Airoldi M., Pedani F., Succo G., Gabriele A.M., Ragona R., Marchionatti S., Bumma C. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer. 2001;91:541–547. doi: 10.1002/1097-0142(20010201)91:3<541::AID-CNCR1032>3.0.CO;2-Y. - DOI - PubMed

LinkOut - more resources